Last reviewed · How we verify

Octreotide Injection — Competitive Intelligence Brief

Octreotide Injection (Octreotide Injection) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Somatostatin analog. Area: Oncology; Endocrinology.

marketed Somatostatin analog Somatostatin receptors (SSTR2, SSTR5) Oncology; Endocrinology Small molecule Live · refreshed every 30 min

Target snapshot

Octreotide Injection (Octreotide Injection) — Centre Hospitalier Universitaire, Amiens. Octreotide is a somatostatin analog that binds to somatostatin receptors to inhibit the secretion of various hormones and reduce blood flow to tumors.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Octreotide Injection TARGET Octreotide Injection Centre Hospitalier Universitaire, Amiens marketed Somatostatin analog Somatostatin receptors (SSTR2, SSTR5)
Signifor PASIREOTIDE Recordati marketed Somatostatin Analog [EPC] Somatostatin receptor type 5 2012-01-01
Somatuline Depot LANREOTIDE Ipsen Pharma marketed Somatostatin Analog Somatostatin receptor type 2 2007-01-01
Sandostatin OCTREOTIDE Novartis marketed Somatostatin Analog Somatostatin receptor type 2 1988-01-01
Pegvisomant/ Sandostatin LAR Pegvisomant/ Sandostatin LAR Pfizer marketed Growth hormone receptor antagonist (pegvisomant); somatostatin analog (octreotide LAR) Growth hormone receptor (pegvisomant); somatostatin receptors, particularly SSTR2 and SSTR5 (octreotide)
Octreotide (drug) Octreotide (drug) Lahore General Hospital marketed Somatostatin analog Somatostatin receptors (SSTR2, SSTR5)
combination with somatostatin analogue octreotide combination with somatostatin analogue octreotide Ludwig-Maximilians - University of Munich marketed Somatostatin analogue Somatostatin receptors (SSTR2, SSTR5)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Somatostatin analog class)

  1. CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · 1 drug in this class
  2. Camurus AB · 1 drug in this class
  3. Cedars-Sinai Medical Center · 1 drug in this class
  4. Centre Hospitalier Universitaire, Amiens · 1 drug in this class
  5. Debiovision · 1 drug in this class
  6. Ipsen · 1 drug in this class
  7. Jiangsu HengRui Medicine Co., Ltd. · 1 drug in this class
  8. Lahore General Hospital · 1 drug in this class
  9. Mario Negri Institute for Pharmacological Research · 1 drug in this class
  10. Memorial Sloan Kettering Cancer Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Octreotide Injection — Competitive Intelligence Brief. https://druglandscape.com/ci/octreotide-injection. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: